Modality
Fusion Protein
MOA
CGRPant
Target
IL-23
Pathway
Checkpoint
Atopic Derm
Development Pipeline
Preclinical
~Mar 2010
→ ~Jun 2011
Phase 1
~Sep 2011
→ ~Dec 2012
Phase 2
~Mar 2013
→ ~Jun 2014
Phase 3
~Sep 2014
→ ~Dec 2015
NDA/BLA
~Mar 2016
→ ~Jun 2017
Approved
Sep 2017
→ Jan 2029
ApprovedCurrent
NCT07690039
1,755 pts·Atopic Derm
2017-09→TBD·Active
NCT03520521
1,233 pts·Atopic Derm
2020-02→2029-01·Recruiting
NCT04953764
1,568 pts·Atopic Derm
2024-07→TBD·Active
+1 more trial
5,257 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2028-05-232.1y awayPh3 Readout· Atopic Derm
2029-01-262.8y awayPh3 Readout· Atopic Derm
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Approved
Active
Approved
Recruit…
Approved
Recruit…
Approved
Active
Catalysts
Ph3 Readout
2028-05-23 · 2.1y away
Atopic Derm
Ph3 Readout
2029-01-26 · 2.8y away
Atopic Derm
RecruitingActive|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07690039 | Approved | Atopic Derm | Active | 1755 | EDSS |
| NCT03520521 | Approved | Atopic Derm | Recruiting | 1233 | CfB |
| NCT04953764 | Approved | Atopic Derm | Active | 1568 | HbA1c |
| NCT06517063 | Approved | Atopic Derm | Recruiting | 701 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF |